[company_age]6.0[/company_age][employees]11-50 employees[/employees][funding]seed[/funding][description]Nimble Science is a Calgary-based company that specializes in the development of innovative technologies for microbiome research. Their flagship product, the SIMBA GI Platform, is a revolutionary tool that allows for the collection of multi-omic data from the entire gastrointestinal tract, including the previously inaccessible small intestine. This data is critical for understanding the role of the microbiome in human health and disease, and it has the potential to revolutionize the way we diagnose and treat a wide range of conditions.

Nimble Science is a relatively young company, having been founded in 2023. However, they have already made significant strides in the field of microbiome research. Their SIMBA GI Platform has been used in a number of clinical trials, and it has been featured in several peer-reviewed publications. The company has also received funding from a number of prestigious investors, including Seventure Partners and Ki Tua Fund.

Nimble Science is led by a team of experienced scientists and entrepreneurs. Dr. Sabina Bruehlmann, the company's CEO, has a PhD in biomedical engineering and over 20 years of experience in the medical device industry. Dr. Joseph Wang, the company's CTO, has a PhD in chemistry and over 15 years of experience in the development of wearable and ingestible technologies.

Nimble Science is a company with a clear mission: to be the leading global collaborator in delivering actionable intelligence from the GI tract to improve health outcomes. They are well-positioned to achieve this mission, given their innovative technology, strong leadership team, and growing list of partners and investors.[/description][ps]SIMBA GI Platform, a revolutionary tool for collecting multi-omic data from the entire gastrointestinal tract.[/ps]